# US 2023/0405189 A1 · Composite material for tissue restoration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405189 A1
- Document ID: US20230405189A1
- Status: Published application
- Kind: A1
- Application number: 18/210,003
- Filed: 2023-06-14
- Published: 2023-12-21
- Earliest claimed: 2014-08-15
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Xuesong Jiang; Sashank Reddy; Gerald Brandacher; Hai-Quan Mao; Justin Sacks; Xiaowei Li; Kevin Feng; Russell Martin; Georgia C. Yalanis; Ji Suk Choi
- Web page: https://patentgrep.com/patent/US20230405189A1

## CPC

- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/16: obtained by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/24: Collagen
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 27/48: with macromolecular fillers
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/06: for cartilage reconstruction, e.g. meniscus
- A61L 2430/34: for soft tissue reconstruction
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A composite material can include a gel and at least one nanostructure disposed within the gel. A method for healing a soft tissue defect can include applying a composite material to a soft tissue defect, wherein the composite material includes a gel and a nanostructure disposed within the gel. A method for manufacturing a composite material for use in healing soft tissue defects can include providing a gel and disposing nanofibers within the gel.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method for manufacturing an injectable scaffold complex, the method comprising the steps of:
providing a three-dimensional scaffold complex comprising polymeric fibers oriented to comprise a plurality of pores; and
mixing a hydrogel material comprising a hyaluronic acid with the polymeric fibers in the presence of an effective amount of a crosslinking moiety to form a scaffold complex, wherein at least a portion of the polymeric fibers are cross-linked to the hydrogel material;
whereby an injectable scaffold complex is manufactured,
wherein the polymeric fibers comprise functional groups, wherein the surface density of the functional groups is from about 10 nmole/mg of fibers to about 160 nmole/mg of the fibers, and
wherein the polymeric fibers comprise a mean diameter of from about 100 nm to about 8000 nm and a mean length of less than about 500 micrometers.

### Claim 22 (depends on 21)

The method of claim 21, wherein the polymeric fibers are capable of dispersing uniformly throughout the hydrogel material, whereby providing isotropic reinforcement to the scaffold complex.

### Claim 23 (depends on 21)

The method of claim 21, wherein the scaffold complex comprises a plurality of pores present on or within a surface of the scaffold complex, wherein the pores are present at a concentration of at least about 50 pores per cm2 of the surface, and wherein at least 80% of the pores have an average pore diameter on the surface is at least about 5 microns.

### Claim 24 (depends on 21)

The method of claim 21, wherein the hydrogel material comprises acrylated hyaluronic acid, and the crosslinking moiety comprises thiolated poly(ethylene glycol), or a derivative thereof.

### Claim 25 (depends on 21)

The method of claim 21, wherein the hydrogel material comprises thiolated hyaluronic acid, and the crosslinking moiety comprises poly(ethylene glycol) diacrylate (PEGDA), or a derivative thereof.

### Claim 26 (depends on 21)

The method of claim 21, wherein the polymeric fibers comprise a synthetic polymeric material comprising a poly(lactic-co-glycolic acid), poly(lactic acid), and/or a polycaprolactone, or a combination or derivative thereof, or a biological polymeric material selected from the group consisting of a silk, collagen, elastin, hyaluronic acid, chitosan, a derivative thereof, and a combination thereof.

### Claim 27 (depends on 21)

The method of claim 21, wherein the hydrogel material comprises a poly(ethylene glycol), a collagen, a dextran, an elastin, an alginate, a hyaluronic acid, a poly(vinyl alcohol), a derivative thereof, or a combination thereof.

### Claim 28 (depends on 21)

A unit dose of the scaffold complex present in a syringe manufactured using the method of claim 21.

### Claim 29

A method for performing a cosmetic procedure or a reconstructive procedure, comprising implanting or injecting an effective amount of a three-dimensional scaffold complex into the tissue to thereby distend it, wherein the scaffold complex comprises a hydrogel network with polymeric fibers, wherein the scaffold complex comprises a crosslinking moiety present in an amount effective to introduce bonding within the hydrogel material,
wherein the polymeric fibers are uniformly dispersed throughout the hydrogel network, and
wherein the polymeric fibers covalently linked to a hydrogel material, and wherein the polymeric fibers are oriented to produce a plurality of pores.

### Claim 30 (depends on 29)

The method of claim 29, wherein the polymeric fibers comprise functional groups and the surface density of the functional groups on the polymeric fibers from about 10 nmole/mg of fibers to about 160 nmole/mg of the fibers, wherein the polymeric fiber comprises a mean diameter of from about 100 nm to about 8000 nm, and wherein the polymeric fibers thereof comprise a mean length of less than 500 micrometers.

### Claim 31 (depends on 30)

The method of claim 30, wherein the hydrogel network comprises acrylated hyaluronic acid, and the crosslinking moiety comprises thiolated poly(ethylene glycol), or a derivative thereof.

### Claim 32 (depends on 30)

The method of claim 30, wherein the hydrogel network comprises thiolated hyaluronic acid, and the crosslinking moiety comprises poly(ethylene glycol) diacrylate (PEGDA), or a derivative thereof.

### Claim 33 (depends on 30)

The method of claim 30, wherein the scaffold complex is capable of being injected through a 21 gauge or smaller gauge needle.

### Claim 34

A method for reducing or reversing a tissue defect resulting from trauma, surgical intervention, or an age-associated disease, disorder or condition, comprising implanting or injecting an effective amount of a three-dimensional scaffold complex into the tissue to thereby distend it, wherein the scaffold complex comprises a hydrogel network with polymeric fibers, wherein the scaffold complex comprises a crosslinking moiety present in an amount effective to introduce bonding within the hydrogel material,
wherein the polymeric fibers are uniformly dispersed throughout the hydrogel network,
wherein the polymeric fibers covalently linked to a hydrogel material, and wherein the polymeric fibers are oriented to produce a plurality of pores.

### Claim 35 (depends on 34)

The method of claim 34, wherein the polymeric fibers comprise functional groups and the surface density of the functional groups on the polymeric fibers from about 10 nmole/mg of fibers to about 160 nmole/mg of the fibers, wherein the polymeric fiber comprises a mean diameter of from about 100 nm to about 8000 nm, and wherein the polymeric fibers thereof comprise a mean length of less than 500 micrometers.

### Claim 36 (depends on 35)

The method of claim 35, wherein the hydrogel network comprises acrylated hyaluronic acid, and the crosslinking moiety comprises thiolated poly(ethylene glycol), or a derivative thereof.

### Claim 37 (depends on 35)

The method of claim 35, wherein the hydrogel network comprises thiolated hyaluronic acid, and the crosslinking moiety comprises poly(ethylene glycol) diacrylate (PEGDA), or a derivative thereof.

### Claim 38 (depends on 35)

The method of claim 35, wherein the tissue defect comprises adipose tissue, pleural tissue, muscle tissue, skin, or a combination thereof.

### Claim 39 (depends on 35)

The method of claim 35, wherein the scaffold complex is capable of being injected through a 21 gauge or smaller gauge needle.

### Claim 40 (depends on 35)

A unit dose of the scaffold complex present in a syringe for use in the method of claim 35.
